HuidaGene Appoints New Members to the Scientific Advisory Board

SHANGHAI and CLINTON, N.J., Apr. 10, 2023 /PRNewswire/ -- HuidaGene Therapeutics (辉大基因; HuidaGene), a global clinical-stage biotechnology company focused on developing genomic medicine, today announced the selection of Drs. Haiyan Jiang and Alvin Luk as the new members of the Scientific Advisory Board (SAB). The SAB, which includes internationally renowned experts in gene and cell therapies, from discovery to translational research, and clinical development across different therapeutic areas, will provide strategic guidance for the global development of HuidaGene's expansive pipeline products.

"To meaningfully alter the course of genetic diseases, we must advance better-validated therapeutic candidates," said Dr. Haiyan Jiang. "My longstanding interest and commitment in gene and cell therapies have led me to HuidaGene's technology platforms that offer a potential cure to diseases with high unmet medical needs, and I am eager to work with the HuidaGene team to move their pipeline forward." 

Dr. Alvin Luk stated, "In looking to the future of the field, I have been impressed with HuidaGene's innovative genome-editing platforms. Dr. Hui Yang has been a long-time leader in CRISPR-based DNA/RNA editing, and I expect that our mutual interests and complementary areas of expertise within gene and cell therapy will be a powerful engine for advancing, and even accelerating, the progess at HuidaGene."

"We are honored to have an accomplished and diverse group of scientific and clinical experts join us as members of our SAB, who represent extensive experience and knowledge in gene and cell therapies, global drug development, and data-driven clinical trial design," said Hui Yang, PhD, Co-Founder, Chief Scientific Advisor, and Chairman of the SAB at HuidaGene. "Haiyan and Alvin are industry veterans who have achieved a number of 'firsts' in gene therapy clinical programs and who will bring deep and relevant development expertise to HuidaGene. With our scientific advisors' leadership, HuidaGene is poised to translate decades of scientific discovery in programmable genome medicines to people living with devastating diseases worldwide," said Xuan Yao, PhD, Co-Founder and Chief Executive Officer of HuidaGene.

About HuidaGene - 辉大基因
HuidaGene Therapeutics (辉大基因) is a global clinical-stage biotechnology company focusing on discovering, engineering, and developing CRISPR-based genetic medicine to rewrite the future of genomic medicine. Based in Shanghai and New Jersey, HuidaGene is committed to addressing patients' needs globally with various preclinical therapeutic programs covering ophthalmology, otology, myology, and neurology. We are currently advancing clinical programs in RPE65 mutation-associated inherited retinal diseases and our preclinical pipeline, including programs in neovascular age-related macular degeneration, retinitis pigmentosa, hereditary hearing loss, Duchenne muscular dystrophy, and MECP2 duplication syndrome. Company's CRISPR-based therapeutics offer the potential to cure patients with life-threatening conditions by repairing the cause of their disease. HuidaGene is committed to transforming the future of genome-editing medicine.

For more information, please visit http://www.huidagene.com
or follow us on LinkedIn at http://www.linkedin.com/company/huidagene 

Details of the additional SAB members' biographies:

Haiyan Jiang, Ph.D. has over 20 years of research and development expertise in biologics, AAV-mediated gene therapy, and in-vivo and ex-vivo CRISPR/Cas9- mediated genome editing products from research to BLA. She has held leadership roles with progressive responsibilities at various companies including Editas Medicine, Biogen, Bayer HealthCare, and Avigen. She led research, preclinical development or clinical pharmacology in the development of ALTUVIIIO, ELOCTATE, ALPROLIX, and JIVI, as well as a number of programs in Phase 1/2a studies. She has over 40 original publications in highly-regarded peer-reviewed journals, including New England Journal of Medicine, Nature Medicine, and Blood; as well as 21 issued US patents. Dr. Jiang received her B.S. in Biochemistry from Fudan University in Shanghai, China, Ph.D. in Oncology from University of Wisconsin-Madison, and postdoctoral training at the University of California-San Francisco.

Alvin Luk, Ph.D., M.B.A., C.C.R.A. brings over 30 years' experience in global drug development, from the bench to the beside through successful commercial launch in small, large, public, and private biotech/biopharma firms, including Shanghai Henlius, Spark Therapeutics (acquired by Roche), Biogen, Bayer HealthCare, Avigen, and Tularik (acquired by Amgen). He is a transformational leader with reputation for navigating through political landscape which leads to a proven track record of more than 250 cumulative total of IND, BLA, and MAA submissions in Americas, Europe, Australia, Japan, and China. Spark Therapeutics' LUXTURNA was approved by US FDA as the first gene therapy in 2017 when he severed as the Head of Clinical Research and Operations. Today, he has participated in the development of 21 approved products. He is the co-author of more than 100 book chapters and scientific papers in highly-regarded peer-reviewed journals, including New England Journal of Medicine, Nature Medicine, Nature, Cell, and Science. Dr. Luk holds an MBA from Harvard Business School and received his Ph.D. in Neuroscience as well as being certified in clinical research from the University of California-San Francisco.

Logo - https://mma.prnewswire.com/media/1990114/Huidagene_Logo.jpg